AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15915008 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol HFA pMDI 24 microg
Number of subjects: 51
Study 15915008 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol HFA pMDI 12 microg
Number of subjects: 51
Study 15915008 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol DPI 24 microg
Number of subjects: 51
Study 15915008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 12870693 — intervention group
Group type: EXPERIMENTAL
Intervention: Livestock-keeping group
Number of subjects: 426
Study 12870693 — intervention group
Group type: COMPARATOR
Intervention: General population group
Number of subjects: 426
Study 10588564 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 7.5 mg/mL, n = 73
Number of subjects: 144
Study 10588564 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 2.5 mg/mL, n = 71
Number of subjects: 144
Study 8916473 — intervention group
Group type: EXPERIMENTAL
Intervention: Procainamide
Number of subjects: 100
Study 8916473 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 100
Study 8916473 — intervention group
Group type: EXPERIMENTAL
Intervention: Procainamide (therapeutic serum levels)
Number of subjects: 100
Study 1908529 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmycin‐metronidazole
Number of subjects: 101
Study 1908529 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim‐sulfamethoxazole
Number of subjects: 101
Study 6685512 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate tape (1 piece, 40 mg/tape)
Number of subjects: 10
Study 6685512 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate tape (2-3 pieces, 40 mg/tape)
Number of subjects: 10
Study 6685512 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 10
Study 31368588 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug filling group (triamcinolone acetonide clotrimazole injected into the external auditory canal)
Number of subjects: 256
Study 31368588 — intervention group
Group type: COMPARATOR
Intervention: Drug smearing group (smearing antifungal cream once per day)
Number of subjects: 256
Study 27836308 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial personalized intervention
Number of subjects: 155
Study 27836308 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 155
Study 26122923 — intervention group
Group type: EXPERIMENTAL
Intervention: Concept approach
Number of subjects: 142
Study 26122923 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad hoc approach
Number of subjects: 142
Study 26122923 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both approaches
Number of subjects: 142
Study 23905372 — intervention group
Group type: EXPERIMENTAL
Intervention: Pengyan Pill (PP) - 10 g each time, thrice daily for 14 consecutive days
Number of subjects: 188
Study 23905372 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin - 10 g each day for 7 consecutive days
Number of subjects: 188
Study 23905372 — intervention group
Group type: EXPERIMENTAL
Intervention: Pengyan Pill (PP)
Number of subjects: 188
Study 23905372 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin
Number of subjects: 188
Study 21692783 — intervention group
Group type: EXPERIMENTAL
Intervention: Jordan Power electric toothbrush
Number of subjects: 45
Study 21692783 — intervention group
Group type: EXPERIMENTAL
Intervention: Panbehriz Classic manual toothbrush
Number of subjects: 45
Study 21692783 — intervention group
Group type: COMPARATOR
Intervention: Jordan toothbrush
Number of subjects: 45
Study 19234829 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized recruitment maneuver (RM) with pressure equal to 15 ml x real body weight/Cdyn + PEEP for 15 s
Number of subjects: 28
Study 19234829 — intervention group
Group type: COMPARATOR
Intervention: Control RM with pressure of 20 cmH2O for 25 s
Number of subjects: 28
Study 16410482 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise program (10-week duration)
Number of subjects: 72
Study 16410482 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised exercise program (1-week supervised instruction followed by 9-week unsupervised home program)
Number of subjects: 72
Study 15277416 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 (4.8 pmol x kg(‐1) x min(‐1))
Number of subjects: 8
Study 15277416 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30-mg tablet of Actos)
Number of subjects: 8
Study 15277416 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with GLP-1 and pioglitazone
Number of subjects: 8
Study 15277416 — intervention group
Group type: COMPARATOR
Intervention: Saline therapy
Number of subjects: 8
Study 11582613 — intervention group
Group type: EXPERIMENTAL
Intervention: Slick Tracy Home Team Program (adapted version)
Number of subjects: 1212
Study 9161093 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive videodisc instruction (IVDI)
Number of subjects: 0
Study 9161093 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture/demonstration
Number of subjects: 0
Study 8487231 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine with 1:100,000 dilution of epinephrine
Number of subjects: 45
Study 8487231 — intervention group
Group type: COMPARATOR
Intervention: Control (no injection)
Number of subjects: 45
Study 2891740 — intervention group
Group type: EXPERIMENTAL
Intervention: Metipranolol drops
Number of subjects: 26
Study 2891740 — intervention group
Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 26
Study 2891740 — intervention group
Group type: EXPERIMENTAL
Intervention: Metipranolol
Number of subjects: 26
Study 31548150 — intervention group
Group type: EXPERIMENTAL
Intervention: Open 'crown' type repair (group A)
Number of subjects: 100
Study 31548150 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous Bunnell type repair (group B)
Number of subjects: 100
Study 30013913 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoleucine supplementation
Number of subjects: 27
Study 30013913 — intervention group
Group type: COMPARATOR
Intervention: Leucine supplementation
Number of subjects: 27
Study 28498185 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Quality Improvement (CQI) intervention
Number of subjects: 511
Study 28498185 — intervention group
Group type: COMPARATOR
Intervention: Control (no CQI intervention)
Number of subjects: 511
Study 25496354 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheath drainage system
Number of subjects: 56
Study 25496354 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-worn urinal (BWU)
Number of subjects: 56
Study 25496354 — intervention group
Group type: EXPERIMENTAL
Intervention: Penile clamp
Number of subjects: 56
Study 25496354 — intervention group
Group type: COMPARATOR
Intervention: Absorbent pads
Number of subjects: 56
Study 23954500 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5mg prasterone (DHEA) administered intravaginally daily
Number of subjects: 0
Study 21364916 — intervention group
Group type: EXPERIMENTAL
Intervention: Model‐free and model‐based connectivity analysis for moral sensitivity task
Number of subjects: 0
Study 18090394 — intervention group
Group type: EXPERIMENTAL
Intervention: NNRTI
Number of subjects: 1379
Study 18090394 — intervention group
Group type: EXPERIMENTAL
Intervention: PI
Number of subjects: 1379
Study 18090394 — intervention group
Group type: EXPERIMENTAL
Intervention: NNRTI plus PI (three-class)
Number of subjects: 1379
Study 18090394 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential adherence (any antiretroviral medication)
Number of subjects: 1379
Study 16647628 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care program
Number of subjects: 71
Study 16647628 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study 12597957 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy (palladium-103 or iodine-125)
Number of subjects: 215
Study 10774095 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin acetate (200 or 400 micrograms every 12 hours)
Number of subjects: 15
Study 10774095 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin acetate (3.6 mg every 21 days)
Number of subjects: 15
Study 8923554 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual search task with Kanizsa-type subjective contours
Number of subjects: 0
Study 8923554 — intervention group
Group type: COMPARATOR
Intervention: Visual search task without subjective contours
Number of subjects: 0
Study 1374040 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (3000 ng infused into the graft over 2 min)
Number of subjects: 33
Study 1374040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 3912026 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 2400 mg (given in two or four equally divided daily doses)
Number of subjects: 144
Study 3912026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 3912026 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (twice daily)
Number of subjects: 144
Study 3912026 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (four times daily)
Number of subjects: 144
Study 31301627 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunlight plus conventional vitamin D supplement (400IU/d)
Number of subjects: 349
Study 31301627 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunlight exposure (7-14 h/week) plus conventional vitamin D supplement (400IU/d)
Number of subjects: 349
Study 28707255 — intervention group
Group type: EXPERIMENTAL
Intervention: Ellips FX phaco handpiece
Number of subjects: 160
Study 28707255 — intervention group
Group type: COMPARATOR
Intervention: Standard phaco handpiece
Number of subjects: 160
Study 25521163 — intervention group
Group type: EXPERIMENTAL
Intervention: ISQ values measured at 0, 2, 4, 8, 12, 16, and 20 weeks postoperation
Number of subjects: 39
Study 25521163 — intervention group
Group type: EXPERIMENTAL
Intervention: ISQ values compared among groups at all observed time points
Number of subjects: 39
Study 24813646 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg ATP daily for 4 weeks
Number of subjects: 244
Study 24813646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 22818021 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg twice daily (2.5 mg twice daily in selected patients)
Number of subjects: 1697
Study 22818021 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 81 to 324 mg daily
Number of subjects: 1697
Study 20603700 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheelchair rugby training (n = 20)
Number of subjects: 40
Study 20603700 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 20)
Number of subjects: 40
Study 17630253 — intervention group
Group type: EXPERIMENTAL
Intervention: Prodromal symptoms
Number of subjects: 339
Study 17630253 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prodrome score
Number of subjects: 339
Study 17630253 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analyses including other potential predictors
Number of subjects: 339
Study 16307657 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg per week
Number of subjects: 583
Study 16307657 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice weekly
Number of subjects: 583
Study 16307657 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (both dosages)
Number of subjects: 583
Study 16307657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 583
Study 12114351 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone 100 microg/d plus zafirlukast 20 mg bid
Number of subjects: 24
Study 12114351 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone 100 microg/d plus theophylline 200 to 300 mg bid
Number of subjects: 24
Study 12114351 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone 400 microg/d
Number of subjects: 24
Study 12114351 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone 100 microg/d plus zafirlukast
Number of subjects: 24
Study 12114351 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone 100 microg/d plus theophylline
Number of subjects: 24
Study 10439754 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusion of 0.1% ropivacaine with 1 microgram/mL sufentanil (R + S)
Number of subjects: 30
Study 10439754 — intervention group
Group type: COMPARATOR
Intervention: Epidural infusion of 0.1% ropivacaine without sufentanil (R)
Number of subjects: 30
Study 10439754 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (R + S and R)
Number of subjects: 30
Study 8560534 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (5 doses distributed every 6 months)
Number of subjects: 3000
Study 8560534 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated village)
Number of subjects: 3000
Study 2518436 — intervention group
Group type: EXPERIMENTAL
Intervention: Different surgical techniques employed in pancreatic allograft
Number of subjects: 0
Study 2518436 — intervention group
Group type: EXPERIMENTAL
Intervention: Various procedures concerning the site of implantation and treatment of exocrine function
Number of subjects: 0
Study 61224 — intervention group
Group type: COMPARATOR
Intervention: Tolmetin sodium (800-1600 mg daily for 12 weeks)
Number of subjects: 38
Study 61224 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolmetin sodium (400-2400 mg daily for 2 years)
Number of subjects: 38
Study 61224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 31842133 — intervention group
Group type: EXPERIMENTAL
Intervention: WBV + BFR
Number of subjects: 50
Study 31842133 — intervention group
Group type: COMPARATOR
Intervention: WBV only
Number of subjects: 50
Study 31176298 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 analog exenatide
Number of subjects: 12
Study 31176298 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 12
Study 28244804 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing delivered in community pharmacies as a standalone service
Number of subjects: 0
Study 28244804 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing integrated into medication therapy management services
Number of subjects: 0
Study 28244804 — intervention group
Group type: COMPARATOR
Intervention: Pharmacogenetic testing delivery
Number of subjects: 0
Study 25367713 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept plus MTX
Number of subjects: 0
Study 25367713 — intervention group
Group type: COMPARATOR
Intervention: MTX
Number of subjects: 0
Study 25367713 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept monotherapy
Number of subjects: 0
Study 23559420 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat PSA test or prostate biopsy within 9 months
Number of subjects: 6294
Study 23559420 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Hispanic black men aged <65 years
Number of subjects: 6294
Study 23559420 — intervention group
Group type: COMPARATOR
Intervention: Older men (≥65 years)
Number of subjects: 6294
Study 20980486 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation with Bifidobacterium breve and Lactobacillus casei
Number of subjects: 231
Study 20980486 — intervention group
Group type: COMPARATOR
Intervention: Control group (human milk without probiotics)
Number of subjects: 231
Study 19807901 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health workers using a 20-sign algorithm to classify newborn illnesses.
Number of subjects: 288
Study 19807901 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health workers recognizing signs and symptoms of newborn illnesses.
Number of subjects: 288
Study 16456408 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor + ranitidine
Number of subjects: 18
Study 16456408 — intervention group
Group type: COMPARATOR
Intervention: Proton pump inhibitor + placebo
Number of subjects: 18
Study 16456408 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor
Number of subjects: 18
Study 15173081 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hyperfractionated accelerated radiotherapy (CHART)
Number of subjects: 402
Study 15173081 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 402
Study 12207595 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene gel 0.1%
Number of subjects: 80
Study 12207595 — intervention group
Group type: COMPARATOR
Intervention: Isotretinoin gel 0.05%
Number of subjects: 80
Study 9707349 — intervention group
Group type: EXPERIMENTAL
Intervention: Epogam (evening primrose oil) - 6 capsules in the morning and 6 capsules in the evening
Number of subjects: 6
Study 7611748 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandwiches chosen based on liking and variety-seeking tendency
Number of subjects: 26
Study 7611748 — intervention group
Group type: EXPERIMENTAL
Intervention: Variety-seeking tendency
Number of subjects: 26
Study 7611748 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice frequencies of sandwich fillings
Number of subjects: 26
Study 2248110 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue exposure and response prevention
Number of subjects: 0
Study 2248110 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 359254 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg diflunisal twice daily
Number of subjects: 31
Study 359254 — intervention group
Group type: COMPARATOR
Intervention: 200 mg oxyphenbutazone 3-times daily
Number of subjects: 31
Study 31234904 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (SB) probiotic intervention for 4 months
Number of subjects: 50
Study 31234904 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 months
Number of subjects: 50
Study 27073000 — intervention group
Group type: EXPERIMENTAL
Intervention: HR-ADM plus standard of care (SOC) applied weekly for up to 12 weeks
Number of subjects: 40
Study 27073000 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) alone
Number of subjects: 40
Study 27073000 — intervention group
Group type: EXPERIMENTAL
Intervention: HR-ADM plus SOC
Number of subjects: 40
Study 27073000 — intervention group
Group type: COMPARATOR
Intervention: SOC alone
Number of subjects: 40
Study 26030112 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulating acupressure
Number of subjects: 300
Study 26030112 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxing acupressure
Number of subjects: 300
Study 26030112 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 300
Study 24151264 — intervention group
Group type: COMPARATOR
Intervention: 28‐mm metal‐on‐metal uncemented total hip replacements (THRs)
Number of subjects: 192
Study 24151264 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid hip resurfacing (HR)
Number of subjects: 192
Study 21188412 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot condition (35°C)
Number of subjects: 9
Study 21188412 — intervention group
Group type: EXPERIMENTAL
Intervention: Cool condition (20°C)
Number of subjects: 9
Study 21188412 — intervention group
Group type: COMPARATOR
Intervention: Control (pre-exercise)
Number of subjects: 9
Study 19661836 — intervention group
Group type: EXPERIMENTAL
Intervention: Low water content (38%, Soflens 38) non‐ionic HCLs
Number of subjects: 16
Study 19661836 — intervention group
Group type: EXPERIMENTAL
Intervention: High water content (66%, Soflens 66) non‐ionic HCLs
Number of subjects: 16
Study 17541827 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical Time Intervention (CTI)
Number of subjects: 0
Study 15517057 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic group treatment (PGT)
Number of subjects: 30
Study 15517057 — intervention group
Group type: COMPARATOR
Intervention: Credible placebo control group (CPC)
Number of subjects: 30
Study 11843242 — intervention group
Group type: EXPERIMENTAL
Intervention: vinorelbine-cisplatin (NVB-P)
Number of subjects: 612
Study 11843242 — intervention group
Group type: COMPARATOR
Intervention: vinorelbine (NVB)
Number of subjects: 612
Study 11843242 — intervention group
Group type: COMPARATOR
Intervention: vindesine-cisplatin (VDS-P)
Number of subjects: 612
Study 9754586 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise performance assessment in symptomatic patients
Number of subjects: 103
Study 9754586 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise performance assessment in asymptomatic patients
Number of subjects: 103
Study 9754586 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analysis of all patients
Number of subjects: 103
Study 7918729 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home comprehensive geriatric assessment (CGA) by geriatric nurse practitioners (GNPs) with yearly assessments, quarterly follow-up visits, and regular telephone contacts.
Number of subjects: 414
Study 7918729 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home comprehensive geriatric assessment (CGA) by GNPs.
Number of subjects: 414
Study 7918729 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified).
Number of subjects: 414
Study 30049729 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble nCPAP and nebulised surfactant (200 mg/kg: poractant alfa)
Number of subjects: 64
Study 30049729 — intervention group
Group type: COMPARATOR
Intervention: Bubble nCPAP alone
Number of subjects: 64
Study 30049729 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble nCPAP and nebulised surfactant
Number of subjects: 64
Study 27688002 — intervention group
Group type: EXPERIMENTAL
Intervention: Organized physical activity intervention (led by instructors)
Number of subjects: 108
Study 27688002 — intervention group
Group type: COMPARATOR
Intervention: Non-physical activity control group
Number of subjects: 108
Study 25979614 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-hydroxyprogesterone caproate (250 mg weekly intramuscular injections)
Number of subjects: 152
Study 25979614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 22853707 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengths based case management
Number of subjects: 36
Study 22853707 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 36
Study 21312264 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-5334 50 mg twice daily
Number of subjects: 285
Study 21312264 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-5334 100 mg once daily
Number of subjects: 285